HeartBeam Launches Pilot Study for On-Demand 12-Lead ECG Patch

Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of deaths each year and often progressing silently until a major cardiac event occurs. As healthcare providers search for faster and more accessible ways to identify high-risk patients earlier, HeartBeam (NASDAQ: BEAT) has launched a new pilot study designed to evaluate its technology — a proprietary on-demand 12-lead ECG patch — in detecting coronary artery disease and inadequate blood flow and oxygen supply to tissue, or ischemia.

“Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time,” said HeartBeam CEO Robert Eno. “The HeartBeam patch is designed to change that. A device capable of generating an on-demand…

The study represents a significant step in the development of the HeartBeam patch, which has the potential to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (“MCT”) markets. By enabling patients to record a 12-lead ECG at any time, the patch could provide clinicians with critical data to detect ischemia earlier, potentially preventing heart attacks and improving outcomes. The pilot study will evaluate the patch's accuracy and usability, paving the way for larger clinical trials and eventual commercialization. If successful, HeartBeam's technology could revolutionize how coronary artery disease is monitored, offering a non-invasive, patient-friendly alternative to current methods that often require hospital visits or bulky equipment.